Please Wait...

Analytical Performance Characteristics of a Novel Immunoassay for Quantification of Neurogranin Truncp75 in Human Cerebrospinal Fluid

E.Chassaing, M.Bodnar-Wachtel, T.Schubert, H.Vanderstichele, E.Stoops, and P.Vergnaud

OBJECTIVES

Despite the fact that the core CSF biomarkers (tau, amyloid) reflect on-going pathology in the brains of subjects with Alzheimer’s Disease (AD), new biomarkers are needed to monitor other hallmarks, such as synaptic degeneration. This study documents the analytical performance characteristics of a novel ELISA, targeting P75 truncated Neurogranin, which has been shown to be the most abundant Neurogranin isoform in CSF.

METHODS

After having performed familiarization runs and adaptation of the test procedures to the needs of a service provider, the assay was challenged internally for its analytical performance characteristics (eg, precision, parallelism, spike-recovery, working range, sample stability) by using commercially available CSF samples (n=32).

RESULTS

The new assay format specifically quantifies Neurogranin truncated at position 75. Full-length Neurogranin is not detected. Neurogranin is quantified in the absence of matrix interference (parallelism 101% ± 8%; dilution range: neat – 1/16). Spike/recovery testing revealed good recovery rates (100% ± 8%). The precision resulted in intra- and inter-assay variability (%CV) below 7% and 13%, respectively. The working range is confirmed between 50 pg/mL (Lower Limit of Quantitation) to 1300 pg/mL (Upper Limit of Quantitation). CSF stability at +4°C is acceptable, but storage at room temperature should not exceed 6 hours; consecutive freezing/thawing of CSF up to 4 cycles did not affect Neurogranin concentrations. The assay format is also applicable to EDTA-plasma samples.

CONCLUSIONS

The newly developed Neurogranin TruncP75 colorimetric ELISA assay meets all internal acceptance criteria for clinical trial sample testing and represents an additional tool for patient management.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Dr Joby John chairing a panel discussion tomorrow 8am at #DIA2019 on ways to improve connectedness of clinical data… https://t.co/BPzi1geKsv
Bioclinica (14 hours ago)
Meet the Bioclinica team at DIA Booth 1831. #DIA2019 https://t.co/pvvdiqJz32 https://t.co/tx4PLDIrMm
Bioclinica (16 hours ago)
We’re at #DIA2019. Visit us at booth #1831 to learn more about our rapidly growing services and meet face to face… https://t.co/rK7V1Aclov
Bioclinica (19 hours ago)
Learn about When EDC is not enough: Automating multi-country data collection and complete workflows at #DIA2019! Ja… https://t.co/zJfytNpz82
Bioclinica (1 week ago)
In San Diego for #DIA2019? Visit us at booth #1831 and meet face to face with our team to learn more about our rapi… https://t.co/T4U4oNXlxo
Bioclinica (2 weeks ago)
We're celebrating International #NASH Day to help raise awareness about non-alcoholic steatohepatitis & fatty liver… https://t.co/16PfGbzeaS
Bioclinica (2 weeks ago)

Latest Blogs:

Medical Imaging of Non-Alcoholic Fatty Liver Diseases in Clinical Trials
EDC Provider Selection
Site Payments Solutions
Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box